Loading...
Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients
BACKGROUND: The anti–programmed cell death 1 (anti–PD-1) antibody pembrolizumab is clinically active against non–small cell lung cancer (NSCLC). In addition to T cells, human natural killer (NK) cells, reported to have the potential to prolong the survival of patients with advanced NSCLC, also expre...
Na minha lista:
| Udgivet i: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society for Clinical Investigation
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7190908/ https://ncbi.nlm.nih.gov/pubmed/32027620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI132712 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|